AbbVie Inc. $ABBV Shares Newly Acquired by First Nebraska Trust Co

First Nebraska Trust Co bought a new stake in shares of AbbVie Inc. (NYSE:ABBV) during the 3rd quarter, according to its most recent filing with the SEC. The fund bought 7,373 shares of the company’s stock, valued at approximately $1,929,000.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Evergreen Private Wealth LLC grew its position in AbbVie by 3.3% in the third quarter. Evergreen Private Wealth LLC now owns 1,090 shares of the company’s stock valued at $285,000 after acquiring an additional 35 shares during the period. Torray Investment Partners LLC lifted its holdings in shares of AbbVie by 0.9% during the third quarter. Torray Investment Partners LLC now owns 83,376 shares of the company’s stock valued at $21,810,000 after acquiring an additional 774 shares during the period. Factory Mutual Insurance Co. lifted its holdings in shares of AbbVie by 6.2% during the third quarter. Factory Mutual Insurance Co. now owns 197,798 shares of the company’s stock valued at $51,742,000 after acquiring an additional 11,548 shares during the period. CrossGen Wealth LLC lifted its holdings in shares of AbbVie by 9.0% during the third quarter. CrossGen Wealth LLC now owns 6,519 shares of the company’s stock valued at $1,705,000 after acquiring an additional 536 shares during the period. Finally, VCI Wealth Management LLC boosted its stake in shares of AbbVie by 36.9% in the 3rd quarter. VCI Wealth Management LLC now owns 12,506 shares of the company’s stock valued at $3,271,000 after purchasing an additional 3,370 shares in the last quarter. Institutional investors own 70.23% of the company’s stock.

Insider Transactions at AbbVie

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the sale, the executive vice president owned 74,430 shares of the company’s stock, valued at $18,607,500. This represents a 30.53% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.06% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

ABBV has been the topic of several analyst reports. Morgan Stanley upped their target price on shares of AbbVie from $310.00 to $346.00 and gave the stock an “overweight” rating in a report on Monday. Weiss Ratings upgraded shares of AbbVie from a “buy (b-)” rating to a “buy (b)” rating in a research report on Thursday, October 8th. The Goldman Sachs Group lifted their price target on shares of AbbVie from $258.00 to $294.00 and gave the company a “neutral” rating in a report on Friday, October 23rd. Sanford C. Bernstein restated a “market perform” rating and issued a $275.00 price target on shares of AbbVie in a research report on Monday. Finally, Argus boosted their price target on shares of AbbVie from $250.00 to $270.00 in a research report on Tuesday, August 4th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, AbbVie presently has an average rating of “Moderate Buy” and an average price target of $296.88.

AbbVie Price Performance

ABBV stock opened at $285.88 on Wednesday. The business has a fifty day moving average price of $270.23 and a 200 day moving average price of $237.89. AbbVie Inc. has a fifty-two week low of $190.75 and a fifty-two week high of $298.74. The stock has a market capitalization of $505.09 billion, a price-to-earnings ratio of 49.20, a P/E/G ratio of 1.31 and a beta of 0.20.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Friday, October 30th. The company reported $3.82 EPS for the quarter, topping analysts’ consensus estimates of $3.73 by $0.09. The company had revenue of $17.40 billion for the quarter, compared to analyst estimates of $17.32 billion. AbbVie had a negative return on equity of 435.41% and a net margin of 15.67%. The business’s revenue was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.86 earnings per share. On average, equities analysts expect that AbbVie Inc. will post 14.00 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, February 16th. Investors of record on Friday, January 15th will be given a dividend of $1.82 per share. This is a positive change from AbbVie’s previous quarterly dividend of $1.73. The ex-dividend date is Friday, January 15th. This represents a $7.28 annualized dividend and a yield of 2.5%. AbbVie’s dividend payout ratio is currently 119.10%.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie raised its 2026 outlook, projecting EPS of $13.95–$13.99 and revenue of $67.8 billion, both slightly above consensus at the midpoint. Its latest quarter also beat analyst estimates, with revenue up 10.3% year over year. Q3 earnings outlook and pipeline progress
• Positive Sentiment: AbbVie expanded its Oxford R&D facility as part of an investment exceeding £120 million, signaling continued commitment to research and development. Reuters: Oxford R&D expansion
• Positive Sentiment: The company expanded its migraine-drug partnership with Brise in a deal potentially worth up to $757 million, adding to its pipeline prospects. AbbVie-Brise license deal
• Positive Sentiment: Several analysts raised their price targets after the quarterly results, reflecting confidence in AbbVie’s growth transition. Analyst target increases
• Negative Sentiment: Fourth-quarter EPS guidance of $3.83–$3.87 is below the $3.89 consensus, despite revenue guidance of $18.4 billion topping expectations. That earnings shortfall could temper the otherwise stronger full-year outlook.
• Negative Sentiment: After a strong run, valuation concerns remain: one recent analysis described the shares as stretched and questioned how much further growth from Skyrizi and pipeline deals is already reflected in the price. Valuation and upside analysis

About AbbVie

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.